CJC 1295 and Ipamorelin have been combined for convenience.
CJC-1295, a medium acting GHRH polypeptide, is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS). It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life. CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans. CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion.
Ipamorelin, a polypeptide, is a growth hormone secretagogue and ghrelin mimetic and analog. Ipamorelin causes significant release of growth hormone by itself, due both to its suppression of somatostatin (an antagonist to GHRH) and stimulation of release of GH from the anterior pituitary, similar to GHRP-2 and GHRP-6 which are from the same class growth hormone releasing peptides.Ipamorelin, a growth hormone secretagogue, is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS). It is a pentapeptide that was derived from GHRP-1. Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.
*The information presented here is intended for educational / informational purposes only.
